ArticlePharmacogenomics2008
Genetic variation in cannabinoid receptor 1 (CNR1) is associated with derangements in lipid homeostasis, independent of body mass index.
Article in Pharmacogenomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Loss of thyroid gland circadian PER2 rhythmicity in aged mice and its potential association with thyroid cancer development.Cell death & disease · 2022Article
- The Endocannabinoid System and Cannabidiol: Past, Present, and Prospective for Cardiovascular Diseases.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Review
- On the Role of Central Type-1 Cannabinoid Receptor Gene Regulation in Food Intake and Eating Behaviors.International journal of molecular sciences · 2021Review
- Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.International journal of obesity (2005) · 2020Review
- Association Between Cannabinoid Receptor-1 Gene Polymorphism and the Risk of Diabetic Nephropathy Among Patients with Type 2 Diabetes Mellitus.Pharmacogenomics and personalized medicine · 2020Article
- Article
- Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues.Cellular and molecular life sciences : CMLS · 2019Review
- Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.Nature reviews. Cardiology · 2018Review
- Association between gene polymorphisms and obesity and physical fitness in Korean children.Biology of sport · 2018Article
- The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.Cardiovascular & hematological disorders drug targets · 2018Review
- Endocannabinoids and endovanilloids: a possible balance in the regulation of the testicular GnRH signalling.International journal of endocrinology · 2013Review
- A common functional promoter variant links CNR1 gene expression to HDL cholesterol level.Nature communications · 2013Article
- Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.Neuroscience · 2012Review
- Article
- Variants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart disease.Obesity (Silver Spring, Md.) · 2011Article
- High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.The pharmacogenomics journal · 2011Review
- A common CNR1 (cannabinoid receptor 1) haplotype attenuates the decrease in HDL cholesterol that typically accompanies weight gain.PloS one · 2010Article
- A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010Article
- Quantification of the clinical modifiers impacting high-density lipoprotein cholesterol in the community: Personalized Medicine Research Project.Preventive cardiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
aimsIn humans, genetic variation in endocannabinergic signaling has been associated with anthropometric measures of obesity. In randomized trials, pharmacological blockade at the level of the cannabinoid receptor 1 (CNR1) receptor not only facilitates weight reduction, but also improves insulin sensitivity and clinical measures of lipid homeostasis. We therefore tested the hypothesis that genetic variation in CNR1 is associated with common obesity-related metabolic disorders. MATERIALS &
methodsA total of six haplotype tagging SNPs were selected for CNR1, using data available within the Human HapMap (Centre d'Etude du Polymorphisme Humain population) these included: two promoter SNPs, three exonic SNPs, and a single SNP within the 3'-untranslated region. These tags were then genotyped in a rigorously phenotyped family-based collection of obese study subjects of Northern European origin. RESULTS &
conclusionsA common CNR1 haplotype (H4; prevalence 0.132) is associated with abnormal lipid homeostasis. Additional statistical tests using single tagging SNPs revealed that these associations are partly independent of body mass index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.